Reimagining the Water Bottle: Jabil Packaging Solutions Launches VITTEL® Hybrid Bottle
9.6.2021 15:47:00 EEST | Business Wire | Press release
Jabil Packaging Solutions, a division of Jabil Inc. (NYSE: JBL), today launched its latest packaging prototype: the Eco.bottle® product platform for VITTEL®, a leading mineral water brand in Europe from the water division of Nestlé. Designed for scalability by a team including Ecologic Brands, acquired by Jabil earlier this year, the VITTEL® hybrid bottle leverages paper and plastic components, resulting in a plastic reduction of more than 50 percent compared to VITTEL®’s current 1-liter bottle. Moreover, this bottle features a patent-pending, first-of-its-kind tear strip, enabling easy separation of the paper and plastic components for an efficient, consumer-friendly recycling experience. This breakthrough innovation is comprised of 100 percent recycled paper and plastic materials, creating a circular system from readily available, high-volume waste streams. Consumer testing in Europe will begin in June and the bottle will be showcased to the media during the upcoming Tour de France, taking place June 26, 2021 through July 18, 2021.
“True innovation in sustainable packaging requires a holistic view of the product that goes beyond aesthetics, material selection and design features,” said Julie Corbett, senior business unit director of Jabil and founder of Ecologic Brands. “Our goal is to innovate around the entire life cycle of the bottle, not only to decrease the use of plastic. That’s why the Eco.bottle® product platform is engineered to drive plastic reduction, improve carbon footprint and optimize the consumer recycling experience.”
Constructed of 80 percent paper and only 20 percent recycled plastic (cap included), the VITTEL® hybrid bottle’s two-shell system, enabled by interlocking paper tabs, allows for nesting during transit and warehousing. This eliminates extra space in the supply chain and has the potential to lessen the amount of trucks needed for delivery by 50-60 percent.
The VITTEL® hybrid bottle project began in 2020; in less than one year, VITTEL® and Jabil have successfully delivered one of the world’s first hybrid water bottles. VITTEL’s deep knowledge of mineral water bottling helped achieve the thinnest 1-liter plastic liner in the market today, which uses just 9.2g of recycled plastic. Jabil’s conversion technology and expertise enabled the fabrication of an elegant and functional outer shell made of certified Forest Stewardship Council reclaimed and recycled material.
“It’s no longer enough for CPG companies to say they’ve reduced their waste. They now also need compelling solutions for repurposing that waste,” said Jason Paladino, senior vice president of Jabil and CEO of Jabil Packaging Solutions. “Jabil’s Box-to-Bottle® manufacturing platform allows us to take our customers' waste and incorporate it into our manufacturing process within our facilities in Manteca, California and Tortosa, Spain. This fully accountable and traceable manufacturing platform provides forward-thinking brands like VITTEL® with unparalleled visibility into the circularity of their products.”
“Thanks to Jabil’s innovative Eco.bottle® product platform, the VITTEL® hybrid bottle is the result of a journey launched several years ago to explore options for drastically reducing the proportion of plastic in our packaging,” said Laure Goutagneux, VITTEL® marketing director. “We are thrilled with the results of our collaboration, including a plastic reduction of 50 percent when compared to our current lightweight bottles.”
About Jabil:
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005197/en/
Contact information
Media Contact
Michelle Smith
VP Communications & Brand Strategy, Jabil
(813) 415-1116
michelle_smith@jabil.com
Investor Contact
Adam Berry
VP Investor Relations, Jabil
(727) 803-5772
adam_berry@jabil.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2026 on July 2 in Munich, Germany. BOT+BAL demonstrated clinically meaningful long-term survival in a heavily pretreated patient population with historically limited benefit from conventional immune checkpoint inhibitors and few durable treatment options after progression on standard therapies. With extended follow-up, median overall survival was 21.2 months and the three-year overall survival rate was 33%, with the Kaplan-Meier curve showing a plateau beyond two years
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 12:12:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to-end AI and cyber exposure assessment engine with a structured execution model that spans from assessment to remediation. At the cor
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 11:00:00 EEST | Press release
Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countries published in “The Allianz 3am Report 2026.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260703907741/en/ Allianz / IPSOS “What Worries the World” Study, April – June 2026. Financial worries, which include concerns about “rising cost of living” (71%) and “insufficient income” (51%), increased in seven out of eight countries surveyed year over year, moving up in the ranking of top three worries in Brazil, France, Germany, and the U.K., while remaining stable in Italy. The strongest increases are observed in Australia and Indonesia, where financial concerns have remained the leading worry, as well
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 09:40:00 EEST | Press release
Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in Tokyo on July 6, 2026. Fusion energy has the potential to shift the foundation of energy from natural resources to advanced technology by reproducing, on Earth, the sam
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 08:15:00 EEST | Press release
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class of payloads for antibody-drug conjugates. The company's platform is built around next-generation N-myristoyltransferase inhibitor (NMTi) payloads, a differentiated mechanism of action designed to address the narrow therapeutic windows and tolerability challenges that have limited earlier generations of ADCs, such as TOPO-1 and tubulin inhibitor payload classes. Myricx Bio's two lead ADC assets, directed towards the established targets B7-H3 and HER2, are designed to bring this differentiated approach to patients across a broad ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom